Researchers use brain wave recordings to successfully predict patient response to common antidepressants.
Two new studies consider the potential of using psychedelics to help treat depression. Imperial College London researchers report psilocybin, the active compound in magic mushrooms, can help to relieve symptoms of depression without the dulling of emotions associated with SSRIs. The researchers note the psychedelic experience could help to maintain long term mental health for those with treatment resistant depression.
A study using rat models of depression reveals a single dose of the cannabis extract CBD can help to reduce symptoms of depression for up to one week. Researchers say cannabidiol appears to activate mechanisms that help repair neural circuitry in the prefrontal cortex and hippocampus, which get damaged as a result of depression.
A new study reports children whose parents divorced when they were teens are less likely to develop depression or use antidepressants as children whose parents spilt up before they were four years old.
A new study reports Zoloft, a commonly prescribed antidepressant alters brain structure differently in those who are depressed and those who aren't.
Sertraline (Zoloft), a commonly prescribed SSRI antidepressant, may not be as effective at treating depression within 6 weeks as previously thought. However, the drug is effective for treating anxiety symptoms.
Mirtazapine, an antidepressant commonly prescribed to treat dementia-associated agitation, is no more effective than a placebo and may increase mortality risks, researchers report.
SSRI antidepressants, such as Prozac and Paxil, interact with opioid medications to make them less effective at providing relief from chronic pain. Tramadol relies on activation of the CYP2D6 enzyme to control pain, but SSRIs inhibit this enzyme. Researchers suggest prescribing different classes of antidepressants which do not suppress the enzyme may benefit those in need of opioid medications. Alternatively, non-opioid pain killers should be considered for those who can not switch from SSRIs.
Researchers have identified a link between anticholinergic medications, including antidepressants and incontinence drugs, and an increased risk of developing dementia later in life.
Anticholinergic drugs, commonly prescribed to treat a range of disorders, from Parkinson's disease to bladder conditions, may increase dementia risks. The increased risk was linked to anticholinergic antidepressants, antipsychotics, bladder control, epilepsy and Parkinson's disease medications. There were no increased risks associated with other types of anticholinergics, such as gastrointestinal drugs or antihistamines.
A synthetic compound, decynium-22, is able to turn off SERT in the brain, enhancing the effectiveness of SSRIs.